Treatment of Egyptian Hepatitis C Genotype 4 Infected Children (and Adolescents) With Combined Sofosbuvir & Daclatasvir
Status:
Completed
Trial end date:
2018-05-18
Target enrollment:
Participant gender:
Summary
This is an open, uncontrolled pilot study of thirty chronic HCV infected patients carried out
at Yassin Abdel Ghaffar Charity Center for Liver Disease and Research. The aim of this study
is to investigate the safety & efficacy of combined therapy sofosbuvir (SOF) and daclatasvir
(DCV) for treating HCV Genotype 4 in children aged 8 to 18. Due to previous positive results
in other clinical studies of this drug it is expected that the drug will have high safety and
high efficacy. Safety will be measured by checking for adverse effects, while efficacy will
be measured by Real-Time Quantitative Polymerase Chain Reaction (qPCR) detecting viral
nucleic acids in blood samples.
Phase:
Phase 3
Details
Lead Sponsor:
Yassin Abdelghaffar Charity Center for Liver Disease and Research
Collaborators:
Egyptian Cure Bank Egyptian Cure Bank NGO Society of Friends of Liver Patients in the Arab World (SLPAW)